|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 21, 22715-22726, May 21, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
as a Positive Regulator of Insulin Sensitivity through Direct Activation of Phosphatidylinositol 3-Kinase in 3T3-L1 Adipocytes*







From the
Division of Endocrinology and Metabolism, Department of Medicine, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan, the ||Department of Biochemistry and the Institute of Development, Aging, and Cancer, Tohoku University, Sendai 980-8575, Japan, and the ¶Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California 92037
Received for publication, December 16, 2003 , and in revised form, February 25, 2004.
| ABSTRACT |
|---|
|
|
|---|
(PP2C
) is increased in 3T3-L1 adipocytes. To elucidate the role of PP2C
in insulin signaling, we overexpressed wild-type (WT) PP2C
by adenovirus-mediated gene transfer in 3T3-L1 adipocytes. Overexpression of PP2C
-WT enhanced the insulin sensitivity of glucose uptake without any changes in the early steps of insulin signaling. Infection with adenovirus 5 expressing PP2C
-WT increased phosphatidylinositol 3-kinase (PI3K) activities in the immunoprecipitate using antibody against the p85 or p110 subunit under both basal and insulin-stimulated conditions, followed by activation of downstream steps in the PI3K pathway, such as phosphorylation of Akt, glycogen synthase kinase-3, and atypical protein kinase C. In contrast, overexpression of the phosphatase-defective mutant PP2C
(R174G) did not produce such effects. Furthermore, overexpression of PP2C
-WT (but not PP2C
(R174G)) decreased the 32P-labeled phosphorylation state as well as the gel mobility shift of the p85 subunit, suggesting that dephosphorylation of the p85 subunit by PP2C
activation might stimulate PI3K catalytic activity. Moreover, knockdown of PP2C
by transfection of small interfering RNA led to a significant decrease in Akt phosphorylation. In addition, microinjection of anti-PP2C
antibody or PP2C
small interfering RNA led to decreased insulin-stimulated GLUT4 translocation. In conclusion, PP2C
is a new positive regulator of insulin sensitivity that acts through a direct activation of PI3K in 3T3-L1 adipocytes. | INTRODUCTION |
|---|
|
|
|---|
) depending on their substrate specificities, bivalent cation dependences, and sensitivities to various inhibitor molecules such as protein inhibitor-1 and -2 and the tumor promoter okadaic acid (3, 5).
The role of protein-tyrosine phosphatases in insulin signaling has been well characterized in several recent studies (6-11). As does tyrosine phosphorylation, serine/threonine phosphorylation plays important roles in insulin signal transduction. A major role in the negative regulation of insulin action is attributed to agents that enhance serine/threonine phosphorylation of the receptor itself or its downstream effectors such as insulin receptor substrate-1 (IRS-1). Serine/threonine phosphorylation of such molecules induces insulin resistance. Furthermore, Akt and atypical protein kinase C
(PKC
) are serine/threonine kinases, and their kinase activities are regulated through the serine/threonine phosphorylation states. These lines of evidence suggest that serine/threonine phosphatases have important roles in insulin signal transduction. However, their roles in insulin signaling are not completely understood (12, 13).
As differentiation proceeds, adipocytes become sensitive to insulin stimulation in terms of glucose uptake. As a proposed molecular mechanism for acquired insulin sensitivity during adipocyte differentiation, the expression levels of important molecules in insulin signaling such as the insulin receptor and IRS-1 have been reported to be up-regulated (14). Furthermore, the level of glucose transporter-4 (GLUT4) is also increased during adipocyte differentiation (15). In this study, we found that the amount of PP2A was decreased during differentiation in 3T3-L1 adipocytes. PP2A is reported to be a negative regulator of insulin signaling in terms of mitogenic signals (12). Thus, the decreased expression of PP2A may be responsible for acquired insulin sensitivity in 3T3-L1 adipocytes. In contrast, we observed that, during differentiation, PP2C
protein expression was increased. Thus, this raises the interesting question of whether up-regulation of PP2C
expression may be responsible for acquired insulin sensitivity by modulating insulin signaling in 3T3-L1 adipocytes. Thus, we clarified the role of PP2C
in the acquisition of additional insulin sensitivity in differentiated adipocytes by three distinct approaches: overexpression of PP2C
by adenovirus-mediated gene transfer, knockdown of PP2C
by transfection or microinjection of small interfering RNA (siRNA), and inhibition of PP2C
function by microinjection of anti-PP2C
antibody.
In this study, we found that overexpression of PP2C
enhanced the insulin sensitivity of glucose uptake. Furthermore, microinjection of PP2C
siRNA or anti-PP2C
antibody led to decreased insulin-stimulated GLUT4 translocation. Decreased insulin sensitivity and decreased insulin responsiveness are two of the major characteristics of insulin resistance states. However, the molecular mechanism for moderation of insulin sensitivity is still unknown. Thus, we examined which step of insulin signaling is modulated by PP2C
overexpression, and we found that PP2C
overexpression directly activated phosphatidylinositol 3-kinase (PI3K), leading to sequential activation of Akt, glycogen synthase kinase-3 (GSK-3), and atypical PKC
without affecting the phosphorylation states of the insulin receptor and IRS-1. These results led us to propose a novel mechanism for potentiation of the PI3K pathway by PP2C
. Thus, we propose that PP2C
may be a new positive regulator of insulin sensitivity in 3T3-L1 adipocytes.
| EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
/
Ser21/9 antibody, and anti-phospho-PKC
Thr403 antibody were from New England Biolabs Inc. (Beverly, MA). Anti-p110
antibody, anti-Akt antibody, horseradish peroxidase-linked anti-rabbit and anti-mouse antibodies, protein A-Sepharose, and protein G-Sepharose were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-PP1 antibody, anti-PP2A antibody, anti-PP2B antibody, anti-PP2C
antibody, anti-IRS-1 antibody, anti-phosphotyrosine antibody 4G10, anti-GSK-3 antibody, and anti-PI3K p85 N-terminal SH2 domain antibody were from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-hemagglutinin (HA) antibody was from Roche Applied Science. Anti-phosphotyrosine antibody RC-20 and anti-PKC
antibody were from Transduction Laboratories (Lexington, KY). Horseradish peroxidase-linked anti-sheep antibody and polyvinylidene difluoride membrane were obtained from Millipore Corp. (Bedford, MA). Anti-His antibody, Dulbecco's modified Eagle's medium (DMEM), and fetal calf serum (FCS) were obtained from Invitrogen. XAR-5 film was obtained from Eastman Kodak Co. All other reagents and chemicals were from standard suppliers. Cell Culture3T3-L1 fibroblasts (American Type Culture Collection, Manassas, VA) were grown and maintained in high glucose DMEM containing 50 units/ml penicillin, 50 µg/ml streptomycin, and 10% FCS in a 10% CO2 environment. The cells were allowed to grow until 2 days post-confluence and then were differentiated as described previously (16). The adipocytes were trypsinized and reseeded in the appropriate culture dishes. The trypsinized adipocytes retained an adipocyte phenotype for at least 10 days after replating as evaluated by noting the extent of lipid droplets by oil red O staining (data not shown). Cells of the adenovirus E1A-transformed human embryonic kidney line (293 cells) were cultured in high glucose DMEM containing 50 units/ml penicillin, 50 µg/ml streptomycin, and 10% FCS in a 5% CO2 environment. Rat1 fibroblasts overexpressing the human insulin receptor (HIRc B cells) as described previously (17) were maintained in DMEM containing 50 units/ml penicillin, 50 µg/ml streptomycin, and 10% FCS in a 5% CO2 environment.
Generation of Mutant PP2C
and Preparation of Recombinant AdenovirusThe recombinant vector containing HA-tagged mouse PP2C
cDNA was generated as described previously (18). A QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used for mutagenesis. An oligonucleotide in which Arg174 of mouse PP2C
was replaced with Gly was used as the primer in the in vitro mutagenesis reaction. Wild-type (WT) and phosphatase-defective (R174G) PP2C
cDNAs were subcloned into the pACCMVpLpASR(+) plasmid (11). This plasmid contains 13 map units of the adenovirus 5 (Ad5) left end, cytomegalovirus early promoter, pUC19 polylinker site, and SV40 poly(A) signal sequences, followed by map units 9-18 of the Ad5 genome. The resulting recombinant plasmids were then cotransfected with the pJM17 plasmid (19) into packaging 293 cells, which carry Ad5 genomic DNA, and propagated as described previously (20). Mature recombinant Ad5 adenoviruses encoding PP2C
-WT and PP2C
-(R174G) were thus generated after in vivo homologous recombination between these two plasmids. Because 293 cells were originally derived from adenovirus transformation, the missing E1 gene function of pJM17 was provided in trans. The resulting recombinant viruses containing PP2C
, denoted as Ad5-PP2C
-WT and Ad5-PP2C
(R174G), were replication-defective (at least in cells lacking the E1 region of the adenovirus), but fully infectious. Ad5-lacZ and Ad5-p110-CAAX (where "A" is aliphatic amino acid) were described previously (21).
Generation of His-tagged Wild-type and Mutant p85 Subunits of PI3KFull-length bovine p85 was provided by Dr. Masato Kasuga (Kobe University, Kobe, Japan) (22). A QuikChange kit was used for site-directed mutagenesis. An oligonucleotide in which Ser608 of bovine pGEX-2T-p85 was replaced with Ala was used as the primer in the in vitro mutagenesis reaction. pGEX-2T-p85-WT and pGEX-2T-p85(S608A) were digested by BamHI and EcoRI and ligated into pcDNA3.1/His (Invitrogen). The resulting plasmids were denoted Hisp85-WT and His-p85(S608A), respectively.
Cell Treatment3T3-L1 adipocytes were infected at a multiplicity of infection (m.o.i.) of 5-50 plaque-forming units/cell for 16 h with stocks of a control recombinant adenovirus (Ad5-ctrl) that contained the cytomegalovirus promoter, the pUC18 polylinker, and a fragment of the SV40 genome, and of the recombinant adenovirus containing lacZ (Ad5-lacZ), PP2C
-WT (Ad5-PP2C
-WT), or PP2C
(R174G) (Ad5-PP2C
(R174G)). Infected cells were incubated for 56 h at 37 °C in high glucose DMEM with 2% heat-inactivated serum, followed by incubation in the starvation medium required for the assay. The survival of the differentiated 3T3-L1 adipocytes was unaffected by incubation of cells with the different adenovirus constructs because the amounts of total cell protein were the same in infected and uninfected cells. HIRc B cells were transfected with 2 µg of each expression plasmid by the LipofectAMINE method. Cells cultured for 48 h were used in the experiments.
Tranfection of siRNAssiRNA for PP2C
(guagucgacaccugcuugutt) and control siRNA (uucuccgaacgugucacgutt) were purchased from QIAGEN Inc. (Germantown, MD). The 3T3-L1 adipocytes reseeded onto 12-well plates were transfected with 2 µg of each siRNA using LipofectAMINE 2000 (Invitrogen). Transfected cells were incubated for 48 h at 37 °C in serum-free medium prior to assays.
Microinjection of Antibodies and siRNAsMicroinjection was carried out using a semiautomatic Eppendorf microinjection system. Antibodies for microinjection were concentrated and dissolved at 5 mg/ml in microinjection buffer containing 5 mM sodium phosphate (pH 7.2) and 100 mM KCl and were injected into the cytoplasm. Sheep IgG (5 mg/ml) was injected into the control cells. siRNA was dissolved at 5 µM in microinjection buffer (23) and injected into the cytoplasm of 3T3-L1 adipocytes.
Western BlottingThe cells were starved for 16 h in regular glucose DMEM containing 0.2% bovine serum albumin; stimulated with 0-100 nM insulin for 5-10 min at 37 °C; and then lysed in solubilization buffer containing 20 µM Tris (pH 7.5), 1 mM EDTA, 140 mM NaCl, 1% Nonidet P-40, 50 units/ml aprotinin, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and 50 mM NaF for 30 min at 4 °C. The cell lysates were centrifuged to remove insoluble materials. Whole cell lysates (20 µg of protein/lane) were denatured by boiling in Laemmli sample buffer containing 100 mM dithiothreitol and resolved by SDS-PAGE. Gels were transferred to nitrocellulose by electroblotting in Towbin buffer containing 20% methanol. For immunoblotting, membranes were blocked and probed with specific antibodies. The blots were then incubated with horseradish peroxidase-linked second antibody, followed by chemiluminescence detection according to the instructions of the manufacturer (Amersham Biosciences). The Western blot data were quantitated by scanning the film using NIH Image.
Northern Blot AnalysisTotal RNA was isolated with TRIzol reagent (Invitrogen), and 20 µg of RNA samples were run on a 1% agarose gel containing formaldehyde and transferred to a nylon membrane (Nytran N, Schleicher & Schüll, Dassel, Germany). The cDNA probes were generated by PP2C
expression vector by enzyme digestion. A cDNA probe labeled with [
-32P]dCTP (PerkinElmer Life Sciences) using a labeling kit (Takara, Shiga, Japan) was hybridized to UV-cross-linked blots overnight at 68 °C in Perfecthybrid hybridization buffer (Toyobo, Tokyo, Japan) and washed at 68 °C for 40 min with 1x trisodium citrate dihydrate and 0.1% SDS. The blots were exposed to Kodak Biomax MR film at -80 °C. The signal was quantitated with a densitometer, and loading differences were normalized to the signal generated with a probe for 18 S ribosomal RNA.
32P Labeling of 3T3-L1 Adipocytes3T3-L1 adipocytes infected with Ad5-ctrl, Ad5-PP2C
-WT, or Ad5-PP2C
(R174G) were starved for 16 h in regular glucose DMEM containing 0.2% bovine serum albumin, followed by phosphate starvation for 2 h in phosphate-free DMEM containing 0.2% bovine serum albumin. [32P]Orthophosphate (0.25 mCi/ml; Amersham Biosciences) was then added, and the cells were cultured for an additional 2 h. The cells were lysed and subjected to immunodepletion with protein A-agarose for 2 h at 4 °C. The resulting supernatants were incubated with anti-p85 antibody and protein A-agarose for 16 h at 4 °C. The immunoprecipitates were denatured by boiling and resolved by SDS-PAGE. The gels were dried and exposed to Kodak Biomax MR film. There was no loading difference as determined by Coomassie Brilliant Blue staining (data not shown).
PP2C
Phosphatase AssayPhosphatase activity was measured using p-nitrophenyl phosphate as a substrate (24) with a phosphatase assay kit (Upstate Biotechnology, Inc.) as described previously (12). Starved cells were lysed in 50 mM HEPES (pH 8.0) containing 150 mM NaCl, 1 mM EGTA, 10% glycerol, 1.5 mM magnesium chloride, 1% Triton X-100, 1 µg/ml leupeptin, 50 units/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride. Cell lysates were incubated with anti-PP2C
or anti-HA antibody and protein G-agarose for 2 h at 4 °C. The immunoprecipitates were washed twice with lysis buffer and once with assay buffer (50 mM Tris (pH 8.0) and 0.1 mM calcium chloride), resuspended in assay buffer containing 2.5 mM nickel chloride and 900 µg/ml p-nitrophenyl phosphate in the absence or presence of 10 mM Mn2+ and 60 mM Mg2+, and incubated for 30 min at 30 °C because PP2C
phosphatase activity is known to be dependent on Mn2+ and Mg2+. The amount of p-nitrophenol produced was determined by measuring the absorbance at 405 nm.
PP2C
Phosphatase TreatmentThe p85 subunit was immunoprecipitated using anti-p85 antibody from lysates of 3T3-L1 adipocytes. The immunoprecipitates were washed twice with lysis buffer and twice with assay buffer, followed by incubation with phosphatase buffer (1 mM EGTA, 0.1% 2-mercaptoethanol, 20 mM imidazole, 1 mg/ml bovine serum albumin, and 20 mM magnesium acetate) with or without 0.4 milliunits of recombinant PP2C
(Upstate Biotechnology, Inc.) for 30 min at 30 °C. After several washes, samples were denatured by boiling and subjected to Western blotting.
Immunostaining and ImmunofluorescenceStaining of LacZ or immunostaining of GLUT4 was performed as described (21, 25). Immunofluorescence microscopy was performed as described previously (23).
2-Deoxyglucose UptakeThe procedure for evaluating glucose transport was a modification of a method described previously (26). Glucose uptake was determined in triplicate at various time points after the addition of 10 µl of substrate. 2-[3H]Deoxyglucose or L-[3H]glucose (0.1 µCi, 0.01 mM final concentration) was add to provide a concentration at which cell membrane transport is rate-limiting. The value for L-glucose was subtracted to correct each sample for the contributions of diffusion and trapping.
PI3K AssaySerum-starved cells (16 h for 3T3-L1 adipocytes and 24 h for HIRc B cells) were incubated in the absence (basal conditions) or presence of 100 nM insulin for 5 min; washed once with ice-cold phosphate-buffered saline; lysed; and subjected to immunoprecipitation (500 µg of total protein) with anti-p110
(2 µg), anti-p85 (4 µg), anti-PP2C
(4 µg), or anti-His (2 µg) antibody for 2 h at 4 °C. Immunocomplexes were precipitated from the supernatant with protein A or G and washed as described (27). The washed immunocomplexes were incubated with phosphatidylinositol (Avanti Polar Lipids) and [
-32P]ATP (3 mCi/mmol) for 10 min at room temperature. Reactions were stopped with 20 µl of 8 N HCl and 160 µl of CHCl3/methanol (1:1); the reaction mixtures were centrifuged; and the lower organic phases were removed and applied to a silica gel TLC plate (Merck) that had been coated with 1% potassium oxalate. TLC plates were developed in CHCl3/CH3OH/H2O/NH4OH (60:47:11.3:2), dried, visualized, and quantitated on a PhosphorImager (Amersham Biosciences).
StatisticsThe values are expressed as means ± S.E., unless otherwise stated. Scheffe's multiple comparison test was used to determine the significance of any differences among more than three groups. p < 0.05 was considered significant.
| RESULTS |
|---|
|
|
|---|
were measured during differentiation of 3T3-L1 fibro-blasts into adipocytes. PP2C
protein expression increased time dependently during differentiation (days 0-7) and reached a level comparable with that in well differentiated adipocytes (days 7-14) (Fig. 1A, upper panel). In contrast, the levels of PP1, PP2A, and PP2B decreased during differentiation. In well differentiated 3T3-L1 adipocytes, the expression levels of PP1, PP2A, and PP2B were only 11.7-32.0% of those in 3T3-L1 fibroblasts (Fig. 1A, lower panel). In contrast, the expression level of PP2C
in adipocytes was increased to 230% compared with that in fibroblasts (Fig. 1A, lower panel). We also observed a significant increase in PP2C
mRNA expression during differentiation (days 0-14) (Fig. 1B).
|
in 3T3-L1 AdipocytesGene transfer into 3T3-L1 adipocytes by conventional methods is inefficient. To achieve sufficient levels of expression, we used adenovirus-mediated gene transfer in terminally differentiated 3T3-L1 adipocytes. To assess infection efficiency, we performed LacZ staining to examine expression of recombinant adenovirus containing the bacterial
-galactosidase gene (Ad5-lacZ) following infection of 3T3-L1 adipocytes at m.o.i. = 50. The infection efficiency was assessed by determining the percentage of cells expressing Ad5-lacZ. >90% of the 3T3-L1 adipocytes showed positive staining on post-infection day 3 as judged by the number of blue cells/200 cells, whereas control adenovirus (Ad5-ctrl)-infected cells exhibited no blue color in the presence of the
-galactosidase chromogenic substrate (Fig. 2A). We next overexpressed PP2C
by adenovirus-mediated gene transfer in 3T3-L1 adipocytes. 3T3-L1 adipocytes were infected with Ad5-ctrl or with recombinant adenovirus expressing HA-tagged wild-type PP2C
(Ad5-PP2C
-WT) or phosphatase-defective PP2C
(Ad5-PP2C
(R174G)). Following a 72-h incubation, the cells were lysed and analyzed by Western blotting with anti-PP2C
or anti-HA antibody (Fig. 2B). Small amounts of endogenous PP2C
were observed in 3T3-L1 adipocytes infected with Ad5-ctrl alone. PP2C
-WT and PP2C
(R174G) were expressed in a dose-dependent manner (Fig. 2B). Furthermore, a 43-kDa band was observed only in Ad5-PP2C
-WT- or Ad5-PP2C
(R174G)-infected cells when immunoblotting was performed using anti-HA antibody (Fig. 2B). A 6-fold increase in PP2C
protein expression was observed in 3T3-L1 adipocytes infected with Ad5-PP2C
-WT or Ad5-PP2C
(R174G) at m.o.i. = 50 compared with that in control cells. To evaluate the effect of PP2C
overexpression on PP2C
phosphatase activity, cell lysates from 3T3-L1 adipocytes infected with Ad5-ctrl, Ad5-PP2C
-WT, or Ad5-PP2C
(R174G) were immunoprecipitated with anti-PP2C
antibody, and in vitro phosphatase activity was measured using p-nitrophenyl phosphate as a substrate with or without Mn2+ and Mg2+(Fig. 2C). Overexpression of PP2C
-WT led to increased phosphatase activity in a dose- and Mn2+-dependent manner to as much as 5-fold at m.o.i. = 50. These enzymatic activities paralleled the PP2C
protein expression levels. Expression of PP2C
(R174G) did not increase phosphatase activity compared with that of PP2C
-WT (Fig. 2C). We measured PP2C
phosphatase activity in the immunoprecipitate using anti-HA antibody to avoid contamination of endogenous PP2C
activity. Overexpression of PP2C
-WT also led to a dose-dependent increase in phosphatase activity. The cells infected with Ad5-ctrl or Ad5-PP2C
(R174G) had no phosphatase activity (Fig. 2C). These results indicate that expression of PP2C
-WT specifically increases PP2C
enzymatic activity and that PP2C
(R174G) is a phosphatase-defective mutant.
|
Overexpression on Insulin-stimulated Glucose Uptake in 3T3-L1 AdipocytesTo examine whether up-regulated PP2C
activity affects insulin-stimulated glucose up-take, we measured insulin-stimulated 2DOG uptake in 3T3-L1 adipocytes infected with Ad5-PP2C
-WT or Ad5-PP2C
-(R174G) (Fig. 3A). Insulin stimulated 2DOG uptake in a dose-dependent manner with ED50 = 0.49 ± 0.11 nM in Ad5-ctrl-infected cells. Overexpression of PP2C
-WT at m.o.i. = 50 increased both the basal and insulin-induced 2DOG uptakes compared with those in control cells (Fig. 3A). Furthermore, overexpression of PP2C
-WT enhanced the insulin sensitivity of 2DOG uptake in an m.o.i.-dependent manner (Fig. 3, B and C). On the other hand, the basal and insulin-induced 2DOG uptakes as well as the insulin sensitivity of 2DOG uptake were not affected by overexpression of PP2C
(R174G) (Fig. 3, A-C). We did not observe any change in GLUT4 expression in any of these cells (Fig. 3D).
|
Directly Activates p85-associated PI3KTo clarify the molecular mechanism for the increased insulin sensitivity of glucose uptake induced by PP2C
overexpression, we next investigated the effect of PP2C
overexpression on the early steps of insulin signaling in 3T3-L1 adipocytes. Compared with the control 3T3-L1 adipocytes, overexpression of PP2C
-WT or PP2C
(R174G) affected neither the degree of insulin-induced tyrosine phosphorylation of either the insulin receptor
-subunit or IRS-1 nor IRS-1 association with the p85 subunit of PI3K (data not shown). These results indicate that PP2C
may not affect the early steps of insulin signaling. To further investigate the insulin signaling, we assessed PI3K activity. Consistent with no change in the association of IRS-1 with the p85 subunit of PI3K, PI3K activity in the immunoprecipitate using anti-phosphotyrosine antibody was not affected by infection with either Ad5-PP2C
-WT or Ad5-PP2C
(R174G) under the basal and insulin-stimulated conditions (data not shown). We next measured PI3K activity in the immunoprecipitate using antibody against the p85 subunit of PI3K. In cells overexpressing PP2C
-WT, the PI3K activity in the immunoprecipitate using anti-p85 subunit antibody was unexpectedly increased by 3-fold under the basal conditions (Fig. 4A). Insulin further increased PI3K activity by 4.5-fold (Fig. 4A). The PI3K activity in the immunoprecipitate using an antibody against the p110 subunit of PI3K was also increased by 2- and 3-fold under the basal and insulin-stimulated conditions, respectively (Fig. 4B). However, the increment of PI3K stimulated by insulin was comparable with that in control cells. Preincubation with 1 µM wortmannin (PI3K inhibitor) blocked the PI3K activity associated with the p110 subunit in cells overexpressing PP2C
-WT (data not shown). On the other hand, PP2C
(R174G) did not affect PI3K activity (Fig. 4, A and B). Moreover, we observed significant PI3K activity in the immunoprecipitate using anti-PP2C
antibody (Fig. 4C). These results confirm that PP2C
directly enhances PI3K activity itself.
|
Overexpression on Akt, GSK-3, and PKC
Phosphorylation in 3T3-L1 AdipocytesTo assess the effect of PP2C
overexpression on further downstream signaling of the PI3K pathway, 3T3-L1 adipocytes overexpressing either PP2C
-WT or PP2C
(R174G) were stimulated with insulin for 10 min, lysed, and analyzed by Western blotting using anti-phospho-Akt, anti-GSK-3, or anti-PKC
antibody. As shown in Fig. 5A, overexpression of PP2C
-WT stimulated Akt phosphorylation at Thr308 and Ser473 in both the absence and presence of insulin. Overexpression of PP2C
-WT also stimulated GSK-3 and PKC
phosphorylation (Fig. 5, B and C). On the other hand, PP2C
(R174G) expression did not affect Akt, GSK-3, or PKC
phosphorylation (Fig. 5, A-C). Furthermore, we observed the enhanced insulin sensitivity of Akt phosphorylation as well as of insulin-stimulated glucose uptake (Fig. 5D). Taken together, these results suggest that PP2C
may activate both the PI3K/Akt/GSK-3 and PI3K/PKC
pathways in 3T3-L1 adipocytes. Furthermore, PI3K activity stimulated by PP2C
directly enhances its downstream signal, without any interaction with the IRS molecule.
|
on Insulin Signaling in 3T3-L1 AdipocytesWe used distinct approaches to clarify the role of endogenous PP2C
functions in insulin signaling. We transfected siRNA into 3T3-L1 adipocytes to knockdown the PP2C
mRNA. Forty-eight hours after transfection, the amount of PP2C
protein was decreased by 37.7 ± 5.4% in PP2C
siRNA-transfected cells compared with that in control siRNA-transfected cells (p < 0.01), whereas expression of PP2A and PP2B was unaffected (Fig. 6A). Akt phosphorylation in adipocytes transfected with PP2C
siRNA was significantly inhibited compared with that in cells transfected with control siRNA (Fig. 6B). To demonstrate the role of endogenous PP2C
in glucose uptake, we next performed a microinjection study with PP2C
siRNA or anti-PP2C
antibody, followed by measurement of GLUT4 translocation, which is rate-limiting for glucose uptake. PP2C
siRNA or anti-PP2C
antibody was microinjected into the cytoplasm of 3T3-L1 adipocytes; and 48 and 72 h later, GLUT4 translocation was measured. Microinjection of PP2C
siRNA or anti-PP2C
antibody decreased insulin-stimulated GLUT4 translocation compared with that in control cells (Fig. 6, C and D). Taken together, these results suggest that PP2C
plays an important role in insulin signaling in glucose metabolism.
|
Affects Glucose Uptake via PI3K in 3T3-L1 AdipocytesTo confirm that PP2C
affects glucose uptake via PI3K activation, we used two approaches. First, we assessed whether constitutively active PI3K could compensate for knockdown of PP2C
. Targeting of the PI3K catalytic subunit to the membrane by the addition of the CAAX signal (p110-CAAX) is known to result in the constitutively active form of PI3K (21). The 3T3-L1 adipocytes were infected with Ad5-ctrl or Ad5-p110-CAAX for 16 h, followed by transfection with control or PP2C
siRNA. Forty-eight hours after transfection, we measured Akt phosphorylation and 2DOG uptake. In the cells infected with Ad5-p110-CAAX, phosphorylation of Akt was enhanced. However, knockdown of PP2C
did not affect Akt phosphorylation induced by constitutively active PI3K (Fig. 7A). Concomitantly, 2DOG uptake induced by p110-CAAX was not affected by knockdown of PP2C
(Fig. 7B). Second, we evaluated whether the PI3K inhibitor wortmannin could block PP2C
-induced phosphorylation of Akt and 2DOG uptake. As shown in Fig. 7 (C and D), wortmannin inhibited PP2C
-enhanced phosphorylation of Akt and 2DOG uptake. Taken together, these findings confirm that the effects of PP2C
on glucose uptake are mediated via PI3K activation.
|
Dephosphorylates the p85 Subunit of PI3K and Activates PI3K ActivitySeveral studies have shown that phosphorylation of the p85 subunit regulates PI3K activity (22, 28, 29). Dhand et al. (22) have shown that the p110 subunit of PI3K has serine/threonine kinase activities as well as lipid kinase activity and that the p110 subunit phosphorylates Ser608 of the p85 subunit, resulting in decreased PI3K activity in an in vitro experiment. Thus, we hypothesized that PP2C
might modulate phosphorylation of the p85 subunit and enhance PI3K activity. To test this hypothesis, we assessed whether PP2C
could modulate phosphorylation of the p85 subunit by performing an in vivo [32P]orthophosphate labeling study. 3T3-L1 adipocytes infected with Ad5-ctrl, Ad5-PP2C
-WT, or Ad5-PP2C
(R174G) were subjected to in vivo 32P labeling. The lysates were immunoprecipitated with anti-p85 subunit antibody, boiled, and resolved by 10% SDS-PAGE. As predicted, infection of cells with Ad5-PP2C
-WT decreased 32P-labeled phosphorylation of the p85 subunit compared with infection of cells with Ad5-ctrl or Ad5-PP2C
(R174G) (Fig. 8A). Furthermore, we performed a gel mobility shift assay with or without PP2C
overexpression. 3T3-L1 adipocytes infected with Ad5-ctrl, Ad5-PP2C
-WT, or Ad5-PP2C
(R174G) were analyzed by SDS-PAGE, followed by Western blotting with anti-p85 antibody (Fig. 8B). The retarded gel mobility shift of the p85 subunit is thought to be caused by increased phosphorylation of the p85 subunit. Overexpression of PP2C
-WT led to subtle but significant reduction of the mobility shift of the p85 subunit (Fig. 8B, lanes 1 and 2), suggesting decreased phosphorylation of the p85 subunit in cells overexpressing PP2C
-WT. In contrast, PP2C
(R174G) overexpression did not affect the mobility shift of the p85 subunit (Fig. 8B, lanes 1 and 3). Moreover, the immunoprecipitate using anti-p85 subunit antibody pretreated with 0.4 milliunits of recombinant PP2C
showed the same reduction in mobility shift as in the PP2C
-WT-overexpressing cells (Fig. 8B, lanes 2 and 5). Tyrosine phosphorylation of the p85 subunit in the immunoprecipitate using anti-p85 antibody was not affected by infection with either virus (data not shown). These data show that the decreased gel mobility indicates dephosphorylation of the serine/threonine residue of the p85 subunit. To further elucidate whether PP2C
might dephosphorylate the putative serine phosphorylation site (Ser608) of the p85 subunit and enhance PI3K activity, we generated His-tagged wild-type p85 and mutant p85 in which Ser608 was replaced with Ala (His-p85(S608A)) and transfected them into HIRc B cells. His-p85-WT and His-p85(S608A) were expressed at identical levels (Fig. 8C). HIRc B cells cotransfected with His-p85-WT or His-p85(S608A) with control, PP2C
-WT, or PP2C
(R174G) vectors were analyzed by SDS-PAGE, followed by Western blotting with anti-His antibody (Fig. 8D). The gel mobility shift assay showed that His-p85(S608A) led to a significant decrease in mobility shift as well as coexpression of p85-WT with PP2C
-WT (Fig. 8D, lanes 2 and 4). We were able to measure the PI3K activity associated with the His-tagged p85 subunit in the immunoprecipitate using anti-His antibody so as to avoid contaminating the activity of the endogenous p85 subunit. As shown in Fig. 8E (lanes 1-3), expression of PP2C
-WT augmented the PI3K activity associated with p85-WT, whereas PP2C
(R174G) had no effect. The protein levels of His-p85 and HA-PP2C
in each sample were identical (Fig. 8E). Interestingly, the p85(S608A)-associated PI3K activity was 3-fold greater than the p85-WT-associated PI3K activity under basal conditions (Fig. 8E, lanes 1 and 4). These results support the ideas that phosphorylation of the p85 subunit at Ser608 may inhibit PI3K activity and that replacement of this serine residue with Ala may prevent inhibition of PI3K by serine phosphorylation. Moreover, expression of PP2C
-WT did not further activate p85(S608A)-associated PI3K activity (Fig. 8E, lanes 4 and 5). In addition, PP2C
-WT did not further decrease the mobility shift of p85(S608A) (Fig. 8D). We have demonstrated here that PP2C
may modulate the phosphorylation states of the p85 subunit and activate PI3K activity.
|
| DISCUSSION |
|---|
|
|
|---|
have been little studied. In this study, we examined the protein expression of serine/threonine phosphatases during 3T3-L1 differentiation and the effects of PP2C
on the insulin signaling pathway. Our study demonstrated that expression of PP2C
was increased during the differentiation of 3T3-L1 adipocytes. Furthermore, adenovirus-mediated overexpression of PP2C
in 3T3-L1 adipocytes significantly enhanced PI3K activity in the immunoprecipitate as evaluated using antibodies against the p85 and p110 subunits of PI3K. We also found increased phosphorylation of Akt, GSK-3, and PKC
, resulting in enhanced insulin sensitivity (reducing ED50 for stimulation) of glucose uptake. However, we found that stimulation of mitogen-activated protein kinase was unaffected by PP2C
overexpression (data not shown), indicating that PP2C
selectively enhances the PI3K pathway (Fig. 9). On the other hand, expression of the phosphatase-defective mutant PP2C
(R174G) did not have such effects. Finally, we demonstrated that microinjection of PP2C
siRNA or anti-PP2C
antibody led to decreased insulin-stimulated GLUT4 translocation.
|
was unexpectedly up-regulated (Fig. 1). Although sequential expression of various genes in adipocyte differentiation has been extensively investigated (30, 31), there is no report on the differentiation-dependent expression pattern of these serine/threonine phosphatases. An earlier study reported that PP2C
is expressed in various human tissues (32), but PP2C
has not been examined in adipose tissue. Thus, we first demonstrated the possible importance of PP2C
in the acquisition by adipocytes of insulin sensitivity during the differentiation process. Molecular cloning has identified PP2C
as a molecule distinct from PP1, PP2A, and PP2B because it constitutes a separate gene family and is a monomeric enzyme (3). Recently, investigations of PP2C
function have revealed a wide range of potential physiological functions (33-36). However, the lack of a specific inhibitor for PP2C
hinders the study of its functions. Thus, we performed a PP2C
overexpression study by the adenovirus-mediated gene transfer technique (Fig. 2). Das et al. (37) examined the molecular structure of PP2C
by crystallographic analysis and reported that PP2C
consists of two domains, an N-terminal catalytic domain with six
-helices and 11
-strands and a 90-residue C-terminal domain with three
-helices. Arg174 is present in the 60-residue segment in the catalytic channel of PP2C
. Marley et al. (38) reported that deletion of the C-terminal residues (including Arg174) results in a completely inactive protein. In addition, replacement of Arg179 (corresponding to Arg174 of PP2C
) with Gly in PP2C
results in a nearly complete loss of enzymatic activity (18). Therefore, Arg174 may be necessary for the phosphatase activity of the protein. Thus, we constructed a PP2C
mutant in which Arg174 was replaced with Gly (PP2C
(R174G)). Although the protein expression level of the mutant was similar to that of PP2C
-WT, the phosphatase activity of PP2C
(R174G) obtained with the anti-PP2C
immunoprecipitate was similar to that obtained in untransfected control cells, and no phosphatase activity was obtained with anti-HA antibody. Thus, we conclude that this mutation disrupted phosphatase activity. Furthermore, this mutant did not have a dominant-negative property. Thus, we used PP2C
(R174G) as a phosphatase-dead enzyme to examine the significance of PP2C
expression as an insulin sensitizer.
One of the major metabolic actions of insulin is stimulation of glucose transport that is mediated in a PI3K-dependent manner. In this study, overexpression of PP2C
-WT enhanced the insulin sensitivity of glucose uptake and also increased both the basal and insulin-stimulated glucose uptakes. In several studies of insulin stimulation of glucose uptake, an approach in which constitutively active signal molecules were expressed in 3T3-L1 adipocytes was adopted (21, 39-44). All of these constitutively active molecules, including PI3K, Akt, and PKC, stimulate 2DOG uptake in the basal state. However, the results are controversial in terms of insulin-stimulated glucose uptake (21, 40-44). Thus, in our opinion, one of the most interesting findings of this study is the evidence that insulin sensitivity is regulated at a site downstream of the insulin receptor and IRS-1 because tyrosine phosphorylation of both proteins was not affected by overexpression of PP2C
. Impaired insulin sensitivity is one of the major characteristics of insulin resistance. Down-regulation of the insulin receptor due to hyperinsulinemia causes decreased insulin sensitivity (45). In contrast, increased expression of the insulin receptor leads to increased insulin sensitivity (17). Furthermore, expression of a dominant-negative kinase-defective insulin receptor impairs tyrosine phosphorylation of IRS-1 (17, 46), resulting in decreased insulin sensitivity. Moreover, increased expression of protein-tyrosine phosphatase-1B decreases tyrosine phosphorylation of both the insulin receptor and IRS-1 and decreases the insulin sensitivity of insulin-stimulated amino acid uptake in the high glucose-induced insulin-resistant state (10). However, the molecular mechanisms that modulate insulin sensitivity are still unclear. This study demonstrates that PP2C
is a positive regulator of insulin sensitivity at the post-IRS-1 level in 3T3-L1 adipocytes, and we propose that modulation of PP2C
activity may be a new therapeutic approach to ameliorate insulin resistance.
Overexpression of PP2C
-WT led to a much higher level of PI3K activity than seen with insulin stimulation alone, but it had only a partial effect on stimulating downstream signaling. Consistent with this, Frevert and Kahn (39) showed that coexpression of both the p110 subunit and the inter-SH2 region of p85 leads to the same results. In addition, when PI3K was activated by thiophosphorylated peptides, only a minor effect on GLUT4 translocation was observed (40). Taken together with our previous result that overexpression of the membrane-localized version of p110-CAAX stimulates glucose uptake in the basal state (21), these studies support the conclusion that active PI3K is sufficient to stimulate insulin signaling only if it is targeted to the proper subcellular membrane compartment. Thus, localization of the p85-p110 complex in the appropriate subcellular compartment is critical for mediating insulin signaling as well as activation of PI3K activity.
In this study, the basal and insulin-stimulated PI3K activities in the immunoprecipitate obtained using anti-p85 and anti-p110 antibodies were increased without any effect on phosphorylation of the insulin receptor and IRS-1 in Ad5-PP2C
-WT-infected cells. These results clearly show the importance of PP2C
in this process, and this raises the question of how PP2C
expression could enhance PI3K activity. The 32P labeling study indicated that PP2C
-WT led to a significant decrease in the phosphorylation state of the p85 subunit. Furthermore, gel mobility shift assay showed that overexpression of PP2C
-WT and pretreatment of recombinant PP2C
led to a significant decrease in p85 subunit phosphorylation. Taken together with the unchanged tyrosine phosphorylation of the p85 subunit, the decreased gel mobility indicated dephosphorylation of the serine/threonine residue of the p85 subunit. These data confirm that PP2C
modulates the phosphorylation state of the p85 subunit.
We further assessed the effect of PP2C
expression on the PI3K activity associated with the p85 subunit. We expressed His-tagged wild-type and putative serine phosphorylation site-mutated p85 subunits, and we successfully measured the PI3K activity associated with the His-tagged p85 subunit to distinguish between the activities of the transfected and endogenous p85 subunits. Cotransfection with His-tagged p85-WT and PP2C
-WT increased PI3K activity. However, cotransfection with His-tagged p85(S608A) and PP2C
-WT had no effect (Fig. 8), suggesting that PP2C
might dephosphorylate the p85 subunit and activate PI3K activity. Furthermore, we demonstrated that PP2C
-WT activated PI3K, but that the phosphatase-dead form did not, suggesting that phosphatase activity is important for enhancement of PI3K activity and that Ser608 of the p85 protein may be the site of dephosphorylation by PP2C
.
We attempted several times to perform mass spectroscopy analysis in vivo to determine the exact phosphorylation site(s). However, the protein amount of the p85 subunit was not sufficient for analysis. Furthermore, we were not able to detect any phosphorylation site(s) of the p85 subunit because of weak signals. It is also possible that the phosphorylated peptide may be degraded by the laser beam during mass spectroscopy analysis and that highly negatively charged peptides from the p85 protein may not be appropriate for mass spectroscopy study. Thus, it is methodologically difficult to obtain direct evidence of the phosphorylation site of serine/threonine by mass spectroscopy analysis of whole cells. A phospho-specific antibody to the putative phosphorylation site is also required to determine the exact sites of dephosphorylation by PP2C
. Thus, determination of the phosphorylation sites of the p85 subunit will require further investigation. Taken together with the results of the 32P labeling study, the gel mobility shift assay, and the mutagenesis study of the p85 subunit, we have demonstrated here that PP2C
activity may directly regulate PI3K activity by dephosphorylating the p85 subunit, although the exact sites of dephosphorylation of p85 require further investigation.
In summary, this study clearly demonstrates that PP2C
increases the insulin sensitivity of glucose uptake and enhances the PI3K pathway. In addition, our results are consistent with the view that PP2C
may be a positive regulator of insulin signaling (Fig. 9). Finally, they demonstrate a novel regulation mechanism for insulin sensitivity through direct activation of PI3K by the serine/threonine phosphatase PP2C
.
| FOOTNOTES |
|---|
To whom correspondence should be addressed: Div. of Endocrinology and Metabolism, Dept. of Medicine, Shiga University of Medical Science, Seta, Otsu, Shiga 520-2192, Japan. Tel.: 81-77-548-2222; Fax: 81-77-543-3858; E-mail: maegawa{at}belle.shiga-med.ac.jp.
1 The abbreviations used are: PP, protein phosphatase; IRS-1, insulin receptor substrate-1; PKC
, protein kinase C
; GLUT4, glucose transporter-4; siRNA, small interfering RNA; PI3K, phosphatidylinositol 3-kinase; GSK-3, glycogen synthase kinase-3; SH2, Src homology-2; HA, hemagglutinin; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; WT, wild-type; Ad5, adenovirus 5; m.o.i., multiplicity of infection; ctrl, control; 2DOG, 2-deoxyglucose. ![]()
| ACKNOWLEDGMENTS |
|---|